Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Operating Expenses (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Operating Expenses data on record, last reported at $71.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 25.48% year-over-year to $71.6 million; the TTM value through Dec 2025 reached $249.3 million, down 27.53%, while the annual FY2025 figure was $249.3 million, 27.53% down from the prior year.
  • Operating Expenses reached $71.6 million in Q4 2025 per MRVI's latest filing, up from -$32.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $120.9 million in Q3 2024 and bottomed at -$67.5 million in Q4 2023.
  • Average Operating Expenses over 5 years is $65.9 million, with a median of $76.6 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: surged 245.0% in 2021, then tumbled 170.65% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $76.6 million in 2021, then rose by 24.55% to $95.5 million in 2022, then crashed by 170.65% to -$67.5 million in 2023, then surged by 184.64% to $57.1 million in 2024, then increased by 25.48% to $71.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $71.6 million in Q4 2025, -$32.1 million in Q3 2025, and $113.7 million in Q2 2025.